Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS: EMMA · Delayed Price · USD
0.100
-0.002 (-1.53%)
May 3, 2024, 3:40 PM EDT - Market closed
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $28.46M in the twelve months ending September 30, 2023, with 83.85% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $5.02M with 1.60% year-over-year growth. In the year 2022, Emmaus Life Sciences had annual revenue of $18.39M, a decrease of -10.77%.
Revenue (ttm)
$28.46M
Revenue Growth
+83.85%
P/S Ratio
0.19
Revenue / Employee
$527,037
Employees
54
Market Cap
5.36M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
Dec 31, 2020 | 23.17M | 415.00K | 1.82% |
Dec 31, 2019 | 22.75M | 21.44M | 1,629.53% |
Sep 30, 2018 | 1.32M | 1.19M | 923.74% |
Sep 30, 2017 | 128.50K | 43.40K | 51.00% |
Sep 30, 2016 | 85.10K | -15.00K | -14.99% |
Sep 30, 2015 | 100.10K | -35.00K | -25.91% |
Sep 30, 2014 | 135.10K | 4.20K | 3.21% |
Sep 30, 2013 | 130.90K | 15.90K | 13.83% |
Sep 30, 2012 | 115.00K | -630.90K | -84.58% |
Sep 30, 2011 | 745.90K | 107.40K | 16.82% |
Sep 30, 2010 | 638.50K | -61.60K | -8.80% |
Sep 30, 2009 | 700.10K | -73.40K | -9.49% |
Sep 30, 2008 | 773.50K | 535.10K | 224.45% |
Sep 30, 2007 | 238.40K | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 6.80K | -1.10K | -13.91% |
Dec 31, 2002 | 7.89K | -383.00 | -4.63% |
Dec 31, 2001 | 8.28K | -5.98K | -41.94% |
Dec 31, 2000 | 14.26K | -5.74K | -28.72% |
Dec 31, 1999 | 20.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
EMMA News
- 18 days ago - Emmaus Life Sciences Reports Delayed Filing of Annual Report - PRNewsWire
- 3 months ago - Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico - PRNewsWire
- 6 months ago - Emmaus Life Sciences Reports Q3 2023 Financial Results - PRNewsWire
- 9 months ago - Emmaus Life Sciences Reports Management Changes - PRNewsWire
- 9 months ago - Emmaus Life Sciences Reports Q2 2023 Financial Results - PRNewsWire
- 10 months ago - Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman - PRNewsWire
- 1 year ago - Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update - PRNewsWire